Literature DB >> 18353924

Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model.

S M Irwin1, A Goodyear, A Keyser, R Christensen, J M Troudt, J L Taylor, A Bohsali, V Briken, A A Izzo.   

Abstract

This study was performed to examine the adaptive immune response generated by three Mycobacterium bovis bacillus Calmette-Guérin (BCG) substrains to determine if the number of genomic regions of deletion played a significant role in determining the magnitude of the immune response or affected their ability to reduce the bacterial burden following low-dose aerosol challenge with a virulent M. tuberculosis strain. BCG Connaught, Pasteur, and Sweden were chosen as representative substrains, as they possessed many, intermediate, and few regions of deletion, respectively, as a result of changes in the genome in various regions. Mice were vaccinated subcutaneously and were then examined at 14, 21, and 42 days postvaccination. BCG was observed in the spleen, lung, and lymph nodes. BCG Connaught induced a greater pulmonary T-cell response than the other two substrains at day 14 postvaccination, although by 42 days postvaccination activated T-cell levels dropped to the levels observed in control mice for all three substrains. Among the three substrains, BCG Connaught induced significantly greater levels of interleukin-12 in bone marrow-derived macrophage cultures. Mice challenged at days 14, 21, and 42 postvaccination displayed an equal capacity to reduce the bacterial burden in the lungs and spleen. The data provide evidence that although the BCG substrains generated qualitatively and quantitatively different immune responses, they induced similar reductions in the bacterial burden against challenge with a virulent M. tuberculosis strain in the mouse model of tuberculosis. The data raise questions about the assessment of vaccine immune responses and the relationship to a vaccine's ability to reduce the bacterial burden.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353924      PMCID: PMC2394844          DOI: 10.1128/CVI.00018-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

1.  Identification of substrains of BCG vaccine using multiplex PCR.

Authors:  J Bedwell; S K Kairo; M A Behr; J A Bygraves
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

Review 2.  Comparative genomics of BCG vaccines.

Authors:  M A Behr
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

Review 3.  BCG--different strains, different vaccines?

Authors:  Marcel A Behr
Journal:  Lancet Infect Dis       Date:  2002-02       Impact factor: 25.071

Review 4.  Correlation between BCG genomics and protective efficacy.

Authors:  M A Behr
Journal:  Scand J Infect Dis       Date:  2001

5.  Rational vaccine development--a new trend in tuberculosis control.

Authors:  Gilla Kaplan
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

6.  Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis.

Authors:  V Gruppo; I M Orme
Journal:  Tuberculosis (Edinb)       Date:  2002       Impact factor: 3.131

7.  Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

Authors:  Marta Romano; Virginie Roupie; Xiao M Wang; Olivier Denis; Fabienne Jurion; Pierre-Yves Adnet; Rachid Laali; Kris Huygen
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 8.  Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree.

Authors:  T Oettinger; M Jørgensen; A Ladefoged; K Hasløv; P Andersen
Journal:  Tuber Lung Dis       Date:  1999

9.  Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

Authors:  Antonia Isabel Castillo-Rodal; Mauricio Castañón-Arreola; Rogelio Hernández-Pando; Juan José Calva; Eduardo Sada-Díaz; Yolanda López-Vidal
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection.

Authors:  D R Roach; H Briscoe; B Saunders; M P France; S Riminton; W J Britton
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  10 in total

1.  Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.

Authors:  Marcela Henao-Tamayo; Andrés Obregón-Henao; Elizabeth Creissen; Crystal Shanley; Ian Orme; Diane J Ordway
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

2.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity.

Authors:  Andrew Keyser; Jolynn M Troudt; Jennifer L Taylor; Angelo A Izzo
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

3.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

4.  Joint effects of host genetic background and mycobacterial pathogen on susceptibility to infection.

Authors:  Tania Di Pietrantonio; José A Correa; Marianna Orlova; Marcel A Behr; Erwin Schurr
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

5.  Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.

Authors:  Elihu Aranday Cortes; Daryan Kaveh; Javier Nunez-Garcia; Philip J Hogarth; H Martin Vordermeier
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

6.  Comparative analysis of immune responses to Mycobacterium abscessus infection and its antigens in two murine models.

Authors:  Bo-Young Jeon; Jeongyeon Kwak; Seung-Sub Lee; Sangnae Cho; Chul Jae Won; Jin Man Kim; Sung Jae Shin
Journal:  J Microbiol       Date:  2009-10-24       Impact factor: 3.422

7.  Characterizing the BCG Induced Macrophage and Neutrophil Mechanisms for Defense Against Mycobacterium tuberculosis.

Authors:  Thomas E Bickett; Jennifer McLean; Elizabeth Creissen; Linda Izzo; Cassidy Hagan; Antonio J Izzo; Fabiola Silva Angulo; Angelo A Izzo
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

8.  Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.

Authors:  Claus Aagaard; Truc Thi Kim Thanh Hoang; Angelo Izzo; Rolf Billeskov; JoLynn Troudt; Kim Arnett; Andrew Keyser; Tara Elvang; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

9.  Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Authors:  Kazuhiro Matsuo; Yasuhiro Yasutomi
Journal:  Tuberc Res Treat       Date:  2011-05-24

10.  A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.

Authors:  Andrea Zelmer; Rachel Tanner; Elena Stylianou; Timon Damelang; Sheldon Morris; Angelo Izzo; Ann Williams; Sally Sharpe; Ilaria Pepponi; Barry Walker; David A Hokey; Helen McShane; Michael Brennan; Helen Fletcher
Journal:  BMC Infect Dis       Date:  2016-08-12       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.